Envoy Group Corp (ENVV) is Pleased to Introduce Natura Coco, a New Louis XIV Energy Drink

 

VALENCIA, California, Dec. 15, 2015 (GLOBE NEWSWIRE) – Envoy Group Corp. (ENVV) is very pleased to introduce to the market another premium beverage in addition to its’ featured line of Louis XIV Energy drinks, Natura Coco.

 

On December 7th 2015, Envoy Group announced its tactical move into the multi-billion dollar beverage market with our exclusive distribution agreement with Austria’s BVD Ltd. The sensational product line of Energy drinks includes Natura Coco; an all-natural coconut water that will target the increasing demand for healthy, effective and natural alternatives for hydration and energy.

 

Envoy recognizes that the coconut water industry has seen exponential growth with only a few active market competitors. Coconut water is now a billion dollar industry and some estimates project the global coconut water market to grow at a compound annual growth rate (CAGR) of 25%.

 

Coconut water is the natural clear liquid found within young green coconuts and has been called natures’ sports drink. A natural hydrator, coconut water, has exploded into one of the fastest growing beverage categories in the U.S. and Europe.

 

Demand for coconut water has risen quickly and coconut water is become a principal beverage served at  food service locations which may lead to coconut water replacing some soda drinks. Currently there is still a huge food service gap in the market for the product.

 

Derived from selected tender fresh coconuts, Natura Coco, possesses low acidity and contains no preservatives or additives. Simplistic and versatile, Natura Coco is excellent at quenching thirst and providing a nutritious, low carbohydrate, natural alternative to other products on the shelf. Natura Coco is fat free, refreshing and full of essential electrolytes.

 

Envoy is extremely excited to be providing this exceptional all-natural energy and hydration drink to the high demand marketplace in 2016.

 

Introduction to Natura Coco:  www.youtube.com and www.instagram.com

For further information please visit our website at: www.envoygroupcorp.com

Louis XIV website link: http://www.louisxivenergy.com/en/

Facebook: www.facebook.com/louisxivenergy/

 

 

Envoy Group Corp.
28494 Westinghouse Place
Suite 213
Valencia, CA 91355

 

Corporate Contact:
Harp Sangha
Chairman, Interim CEO & CFO
Email:   hsangha@envoygroupcorp.com

Investor Relations Contact:
Stuart Smith, Investor Relations
Tel:        1-512-267-2430
Email:   ssmith@smallcapvoice.com

 

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates”, “intends” or “believes”, or that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, or “be achieved”. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.